Pivotal Data in NHL and Pediatric Cancers at ASH 2021: Insight From Drs. Loretta Nastoupil and Michael Pulsipher

Now Viewing

EP: 1.Pivotal Data in NHL and Pediatric Cancers at ASH 2021: Insight From Drs. Loretta Nastoupil and Michael Pulsipher

EP: 2.Exciting Results Ignite in Multiple Myeloma and CLL at ASH 2021: Perspectives From Drs Nina Shah and Jacqueline Barrientos

EP: 3.Updates in AML and MPNs From ASH 2021: From Drs Srdan Verstovsek and Naval Daver

Today-

We are reporting from the 2021 ASH Annual Meeting!

We are been highlighting some of the top news presented each day during the meeting—and soon we’ll speak with Dr. Loretta Nastoupil on some exciting non-Hodgkin lymphoma studies, Dr. Jacqueline Barrientos on the latest in chronic lymphocytic leukemia, Dr. Michael Pulsipher on some intriguing pediatric cancer research.

Welcome to OncLive News Network! I’m Gina Mauro.

Updated results from the phase 2 GRIFFIN trial showed that the combination of daratumumab, lenalidomide, bortezomib, and dexamethasone continued to demonstrate deep and durable responses, including stringent complete response and minimal residual disease negativity, in patients with transplant-eligible newly diagnosed multiple myeloma.

In the phase 2 HOVON 143 trial, intermediate-fit patients with multiple myeloma were found to benefit from ixazomib, daratumumab, and dexamethasone. However, treatment discontinuation due to toxicity does remain a concern with this combination.

In light chain amyloidosis, an 18-month analysis of the phase 3 ANDROMEDA study showed that subcutaneous daratumumab with bortezomib, cyclophosphamide, and dexamethasone demonstrate sustained clinical benefits vs VCd alone in terms of hematologic and organ responses with longer follow-up. However, many patients in the D-VCd arm received single-agent daratumumab monotherapy following 6 cycles of D-VCd, and patients in the VCd group stopped study treatment.

MRD guided time-limited treatment with ibrutinib and venetoclax in patients with relapsed/refractory chronic lymphocytic leukemia who have undetectable MRD is feasible and demonstrates a favorable benefit-risk profile, according to a primary analysis from the phase 2 VISION HO141 trial.

Also in CLL, the all-oral, once-daily, fixed-duration combination of ibrutinib and venetoclax demonstrated superior undetectable MRD responses that were deeper and better sustained post-treatment vs chlorambucil/obinutuzumab in elderly or unfit patient with previously untreated disease, as seen in the phase 3 GLOW study.

Please be sure to check out more of our coverage from the 2021 ASH Annual Meeting at OncLive.com.

That’s all for today. Tomorrow, we will sit down virtually with Dr. Nina Shah, who will unpack pivotal results in multiple myeloma.

Thank you for watching OncLive News Network: On Location, I’m Gina Mauro.